导师风采
桑新亭

个人信息

Personal Information

  • 性别:男
  • 导师类型:博导
  • 职称:主任医师
  • 该职称任职时间:14

联系方式

Contact Information

  • 所属院系:北京协和医院
  • 所属专业:
  • 邮箱 : sangxt@pumch.cn
  • 工作电话 : 13901393467

个人简介

Personal Profile

桑新亭,男,主任医师、教授、博士生导师,原北京协和医院肝脏外科主任。1986年毕业于中山医科大学,后进入北京协和医院外科,历任住院医师、主治医师、副主任医师、主任医师、教授。擅长疑难重症肝胆疾病外科诊疗,研究方向为肝胆恶性肿瘤基础研究与外科诊疗。于1993年到1995年在瑞典Karolinska学院做访问学者。先后承担863项目、国家自然基金项目、科技部国际合作项目、卫计委行业基金等多项国家级、省部级项目。社会兼职包括欧美同学会医师协会肝胆分会主任委员,中国微循环学会肝脏专业委员会主任委员,HBSN杂志(IF:8.265)编委,中国医师协会内镜分会委员,中华普通外科学文献编委,协和医学杂志编委,北京协和医院移植伦理委员会副组长。近10年发表SCI文章100余篇,总影响因子超过500,其中以通讯作者发表SCI文章40余篇。

团队简介

Team Profile

桑新亭教授从事肝胆肿瘤研究30余年,具有丰富的临床研究和基础科研研究背景。目前所带领的研究团队由具有分子生物学、生物信息专业背景的科研博士后、研究生和肝胆外科专业的临床型研究生共同组成。研究团队既能完成临床样本的妥善收集整理,又能实现各维度测序及生信数据的深入挖掘和分析。所在科室每年行外科手术1000余例,其中2/3以上为恶性肿瘤切除手术,目前团队已积累包括石蜡样本及新鲜冻存组织在内的肝癌各期手术样本2000余例,并建立了完善的病例资料档案,设专人定期随访。另外,团队与中科院计算所、北京大学、清华大学和中国医学科学院大数据中心等多个科研/学术机构有着稳定的合作和互访。

  • 研究方向Research Directions
肝胆恶性肿瘤精准免疫治疗
  • 在校研究生Current Graduate Students

硕士研究生 0 名,博士研究生 3 名

  • 科研项目Research Projects
# 项目名称 起止日期 金额 项目类型 本人角色
1中国罕见病的精准诊疗研究2021-01-12 —— 2025-1180.0主持人
  • 发表论文Papers
# 论文题目 期刊名称 发表年份 论文署名
1The fusion landscape of hepatocellular carcinoma.MOLECULAR ONCOLOGY2019-03通讯作者
2The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review. CELL PROLIFERATION2020-04通讯作者
3Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysisBrief Bioinform2021-07通讯作者
4Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review Cell Prolif.2020-01通讯作者
5Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients.Int Immunopharmacol2020-11通讯作者
6 Construction of a new immune-related signature based on three lncRNAs as the factor for prognosis prediction of hepatocellular carcinoma.Clin Transl Med2020-06通讯作者
7Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of T stage in hilar cholangiocarcinomaCancer Management and Research2019-06-04通讯作者
8The fusion landscape of hepatocellular carcinomaMolecular Oncology2019-05-01通讯作者
9DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinomaTheranostics2019-09-25通讯作者
10Development of an Immune-related Prognostic Index Associated with Hepatocellular CarcinomaAging-US2020-03-02通讯作者
11Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinomaCancer Medicine2020-07-16通讯作者
12CK20 and lymph node involvement predict adverse outcome of malignant intraductal papillary neoplasm of the bile ductHISTOLOGY AND HISTOPATHOLOGY2020-05-01通讯作者
13Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysisBRIEFINGS IN BIOINFORMATICS2021-07-20通讯作者
14N6-methyladenosine associated prognostic model in hepatocellular carcinomaANNALS OF TRANSLATIONAL MEDICINE2020-05-01通讯作者
15Cerna Regulatory Network Based Analysis to Study the Roles of Noncoding Rnas in the Pathogenesis of Intrahepatic Cholangiocellular CarcinomaAging-US2020-01-31通讯作者
16Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapyHEPATOBILIARY SURGERY AND NUTRITION2021-08-11通讯作者
17A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancerCANCER IMMUNOLOGY IMMUNOTHERAPY2022-01-13通讯作者
18A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscapeGENOME MEDICINE2022-02-24通讯作者
19Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysisBrief Bioinform2021-07-01通讯作者
20Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon AdenocarcinomaFrontiers in Cell and Developmental Biology2022-07-13通讯作者
21Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinomaAnnals of Translational Medicine2022-07-15通讯作者
22Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancerAmerican Journal of Cancer Research2023-04-29通讯作者
23Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancerFrontiers in Immunology2023-01-18通讯作者
24Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitorsHepatobiliary Surgery and Nutrition2023-06-15通讯作者
25Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancersTranslational Research2023-06-01通讯作者
26Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinomaBMC CANCER2023-05-18通讯作者
27Pancreatic ductal adenocarcinoma with synchronous and metachronous hepatic metastasis predicted by contrast- enhanced ultrasoundQUANTITATIVE IMAGING IN MEDICINE AND SURGERY2023-06-01通讯作者
28T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapyAmerican Journal of Cancer Research2020-10-01通讯作者
29The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A reviewCELL PROLIFERATION2020-02-22通讯作者
30Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A reviewCELL PROLIFERATION2020-01-15通讯作者
31Liver graft rejection following immune checkpoint inhibitors treatment: a reviewMEDICAL ONCOLOGY2019-09-09通讯作者
32Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular CarcinomaINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS2024-05-10通讯作者
33Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancerBiomarker Research2024-06-03通讯作者
34Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature reviewANNALS OF TRANSLATIONAL MEDICINE2019-12-01通讯作者
35Urinary biomarkers for hepatocellular carcinoma: current knowledge for cliniciansCancer Cell International2023-10-28通讯作者
  • 科研获奖Research Awards
# 获奖证书编号 奖项名称 获奖级别 获奖类别 获奖等级 获奖日期 颁奖单位 本单位是否为第一完成单位 完成单位排名 本人排序 备注
1201903199P0802以MDT为基础的肝胆系恶性肿瘤精准免疫治疗体系的建立与推广省部级其他省部级奖励三等奖2020-01-18中华医学会12共同获奖人
  • 研究成果Research Findings
# 成果类型 项目/专利/新品种名称
1作为主创人员获得授权的发明专利和新品种应用Ehida、GSA评估肝脏储备功能和肝切除的可行性
2获得省部级及以上科研奖励以MDT为基础的肝胆系恶性肿瘤精准免疫治疗体系的建立与推广